利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.102 秒)

    CSF biomarker dilution factor corrections by MRI imaging and algorithm
    1.
    发明申请
    CSF biomarker dilution factor corrections by MRI imaging and algorithm 审中-公开

    公开(公告)号：US20120191360A1

    公开(公告)日：2012-07-26

    申请号：US13385440

    申请日：2012-02-21

    申请人： Mony De Leon ,  Henry Rusinek

    发明人： Mony De Leon ,  Henry Rusinek

    IPC分类号： G06F19/00

    CPC分类号： A61B5/48 ,  A61B5/055 ,  A61B5/1075 ,  A61B5/4088 ,  G01N33/6896

    摘要： A method is disclosed for providing a correcting factor for the dilution of measurements of at least one biomarker in cerebrospinal fluid (CSF). The method comprises providing semi-automated measurements of the ventricular system by MRI scans using quantitative anatomical protocols, determining a measurement of biomarker levels in CSF that has been extracted, correcting the measurement of the level of said at least one biomarker'according to the ventricular size, and providing a corrected result of the measurement determined in step (b), said corrected result accounting for concentration dilution due to the change in ventricular size. The method is particularly suited for the measurement of all biomarkers found in the CSF, such as those associated with mild cognitive impairment (MCI) and Alzheimer's Disease.

    Treatment or diagnosis of diseases or conditions associated with a BLM domain
    4.
    发明授权
    Treatment or diagnosis of diseases or conditions associated with a BLM domain 失效
    治疗或诊断与BLM结构域相关的疾病或病症

    公开(公告)号：US06045797A

    公开(公告)日：2000-04-04

    申请号：US866381

    申请日：1997-05-30

    申请人： Ben Lewis Margolis ,  Joseph Schlessinger

    发明人： Ben Lewis Margolis ,  Joseph Schlessinger

    IPC分类号： A61P43/00 ,  C07K14/475 ,  C07K14/485 ,  C07K14/71 ,  A61K39/00 ,  C07K1/00

    CPC分类号： C07K14/485 ,  C07K14/475 ,  C07K14/71

    摘要： A method for treatment of a disease or condition in an organism characterized by an abnormal level of interaction between a BLM domain and its natural binding partner is described. The disease or condition may also be characterized by an abnormality in a signal transduction pathway, wherein the pathway contains a protein with a BLM domain. The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complex formed between the BLM domain-containing protein and its natural binding partner. A method for diagnosis of such a disease or condition by detecting the level of such interaction as an indication of that disease or condition is also described. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described. The invention also features a peptide comprising, consisting or consisting essentially of a BLM domain.

    摘要翻译： 描述了用于治疗生物体中疾病或病症的方法，其特征在于BLM结构域与其天然结合配偶体之间的相互作用异常水平。 疾病或病症的特征还在于信号转导途径的异常，其中该途径含有具有BLM结构域的蛋白质。 该方法包括在体内破坏或促进相互作用（或信号）。 该方法还涉及抑制在含有BLM结构域的蛋白质与其天然结合配偶体之间形成的复合物的活性。 还描述了通过检测这种相互作用的水平来诊断这种疾病或病症的方法，作为该疾病或病症的指征。 此外，描述了通过测定潜在剂以破坏或促进该相互作用的能力来筛选可用于治疗这种疾病或病症的药剂的方法。 本发明还特征在于肽，其包含由BLM结构域组成或由其组成。

    Growth factor inducible serine/threonine phosphatase FIN13
    6.
    发明授权
    Growth factor inducible serine/threonine phosphatase FIN13 失效
    生长因子诱导型丝氨酸/苏氨酸磷酸酶FIN13

    公开(公告)号：US5976853A

    公开(公告)日：1999-11-02

    申请号：US822701

    申请日：1997-03-21

    申请人： Mark A. Guthridge ,  Claudio Basilico

    发明人： Mark A. Guthridge ,  Claudio Basilico

    IPC分类号： C07H21/00 ,  C12N9/16 ,  C07H21/04

    CPC分类号： C07H21/00 ,  C12N9/16 ,  C12N2799/021

    摘要： A novel serine/threonine phosphatase, FIN13, which includes a collagen-homology domain, an acidic box domain, a catalytic domain, and a putative nuclear translocation sequence. The present invention further relates to the modulation of cellular proliferation, by regulating the activity of the novel serine/threonine phosphatase. Thus, the invention provides the phosphatase, nucleic acids encoding the phosphatase, oligonucleotides specific for such nucleic acids, antibodies to the phosphatase, and methods for increasing (or decreasing) the activity of the phosphatase to inhibit (or enhance) cellular proliferation and, thus, tissue growth. Various diagnostic and therapeutic aspects of the invention particularly relate to detection and treatment of hyperproliferative disorders, neoplasms, and tumors. In specific examples, FIN13 is expressed in proliferating cells, notably gern cells of the testes. Increased levels of expression of FIN13 in transfected cells results in a decrease in the cell growth rate.

    摘要翻译： 一种新型的丝氨酸/苏氨酸磷酸酶FIN13，其包括胶原同源结构域，酸性盒结构域，催化结构域和推定的核易位序列。 本发明还涉及通过调节新型丝氨酸/苏氨酸磷酸酶的活性来调节细胞增殖。 因此，本发明提供磷酸酶，编码磷酸酶的核酸，对这种核酸特异的寡核苷酸，对磷酸酶的抗体，以及增加（或降低）磷酸酶活性以抑制（或增强）细胞增殖的方法，因此 ，组织生长。 本发明的各种诊断和治疗方面特别涉及过度增殖性疾病，肿瘤和肿瘤的检测和治疗。 在具体实例中，FIN13在增殖细胞中表达，特别是睾丸的ern细胞。 转染细胞中FIN13的表达水平升高导致细胞生长速率降低。

    CSF biomarker dilution factor corrections by MRI imaging and algorithm
    8.
    发明授权
    CSF biomarker dilution factor corrections by MRI imaging and algorithm 失效
    CSF生物标记稀释因子校正通过MRI成像和算法

    公开(公告)号：US07736623B2

    公开(公告)日：2010-06-15

    申请号：US10508065

    申请日：2003-03-20

    申请人： Mony De Leon ,  Henry Rusinek

    发明人： Mony De Leon ,  Henry Rusinek

    IPC分类号： A61B5/055 ,  G01N33/53 ,  G01N33/542 ,  G01N33/566 ,  C12Q1/00

    CPC分类号： A61B5/48 ,  A61B5/055 ,  A61B5/1075 ,  A61B5/4088 ,  G01N33/6896

    摘要： A method is disclosed for providing a correcting factor for the dilution of measurements of at least one biomarker in cerebrospinal fluid (CSF). The method comprises providing semi-automated measurements of the ventricular system by MRI scans using quantitative anatomical protocols, determining a measurement of biomarker levels in CSF that has been extracted, correcting the measurement of the level of said at least one biomarker according to the ventricular size, and providing a corrected result of the measurement determined in step (b), said corrected result accounting for concentration dilution due to the change in ventricular size. The method is particularly suited for the measurement of all biomarkers found in the CSF, such as those associated with mild cognitive impairment (MCI) and Alzheimer's Disease.

    摘要翻译： 公开了一种提供用于稀释脑脊液（CSF）中的至少一种生物标志物的测量的校正因子的方法。 该方法包括通过使用定量解剖方案的MRI扫描提供心室系统的半自动测量，确定已经提取的CSF中的生物标志物水平的测量，根据心室尺寸校正所述至少一种生物标志物的水平的测量 ，并提供在步骤（b）中确定的测量的校正结果，所述校正结果考虑了由于心室大小变化引起的浓度稀释。 该方法特别适用于测量CSF中发现的所有生物标志物，例如与轻度认知障碍（MCI）和阿尔茨海默病相关的那些。